Pro- and anti-tumor effects of wedelolactone in breast cancer cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F13%3A00065616" target="_blank" >RIV/00216224:14310/13:00065616 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Pro- and anti-tumor effects of wedelolactone in breast cancer cells

Popis výsledku v původním jazyce

Natural phytocompounds and their derivatives are commonly used for prevention and treatment of various diseases, including cancer. Wedelolactone is one of the active polyphenolic compounds in extracts of Wedelia calandulaceae and Eclipta prostrata. Wedelolactone was shown to inhibit growth of breast and prostate cancer cells in vitro and in vivo. The growth inhibitory effects of wedelolactone have been largely attributed to the inhibition of IKK kinase, the key enzyme regulating the activity of NFkB. Wehave recently described that wedelolactone inhibits DNA synthesis and acts as catalytic inhibitor of DNA topoisomerase IIalpha. This study was designed to characterize the mechanisms of wedelolactone effects on breast cancer cells in detail. We observedthat in nM concentrations, wedelolactone stimulates growth of ER-positive breast cancer cells MCF-7 and T47D by activation of genomic ER-signalling pathway. This growth-stimulatory effect was not detected in ER-negative MDA-MB-231 breast

Název v anglickém jazyce

Pro- and anti-tumor effects of wedelolactone in breast cancer cells

Popis výsledku anglicky

Natural phytocompounds and their derivatives are commonly used for prevention and treatment of various diseases, including cancer. Wedelolactone is one of the active polyphenolic compounds in extracts of Wedelia calandulaceae and Eclipta prostrata. Wedelolactone was shown to inhibit growth of breast and prostate cancer cells in vitro and in vivo. The growth inhibitory effects of wedelolactone have been largely attributed to the inhibition of IKK kinase, the key enzyme regulating the activity of NFkB. Wehave recently described that wedelolactone inhibits DNA synthesis and acts as catalytic inhibitor of DNA topoisomerase IIalpha. This study was designed to characterize the mechanisms of wedelolactone effects on breast cancer cells in detail. We observedthat in nM concentrations, wedelolactone stimulates growth of ER-positive breast cancer cells MCF-7 and T47D by activation of genomic ER-signalling pathway. This growth-stimulatory effect was not detected in ER-negative MDA-MB-231 breast

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13441" target="_blank" >NT13441: Exprese proteinů rodiny Myb v adenokarcinomech tlustého střeva a vztah k jejich metastatickému potenciálu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů